• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

54.41 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
June 22, 2026
From Exelixis, Inc.
Via Business Wire
Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Health ↗
June 09, 2026
Via Chartmill
News headline image
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
May 30, 2026
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
May 30, 2026
From Exelixis, Inc.
Via Business Wire
EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Case for Value Investors ↗
May 14, 2026
Via Chartmill
Exelixis Beats Q1 Estimates and Advances Pipeline, Driving EXEL Momentum ↗
May 05, 2026
Via Chartmill
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
May 27, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near ↗
May 23, 2026
Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president... 
Via MarketBeat
News headline image
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
May 21, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal ↗
May 20, 2026
NCR Atleos delivers self-service banking technology and managed services to financial institutions and enterprise clients worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
Exelixis Inc (NASDAQ:EXEL) Passes the Caviar Cruise Quality Screen with Zero Debt and 54% ROIC ↗
April 29, 2026
Via Chartmill
Exelixis Inc. (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
March 31, 2026
Via Chartmill
News headline image
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
May 19, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
Prediction: This Stock Could Double By 2031 ↗
May 15, 2026
It's not the most prominent company in its industry, but it is definitely worth a second look. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
May 07, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis (EXEL) Q1 2026 Earnings Transcript ↗
May 05, 2026
Exelixis (EXEL) Q1 2026 Earnings Transcript 
Via The Motley Fool
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
February 26, 2026
Via Chartmill
News headline image
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 05, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
April 21, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
April 16, 2026
These companies boast significant upside potential. 
Via The Motley Fool
Exelixis Inc. (NASDAQ:EXEL) Stands Out as a Quality Investing Candidate ↗
February 19, 2026
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue ↗
February 10, 2026
Via Chartmill
News headline image
Exelixis: A Strong Contender in the Cancer Drug Market ↗
March 31, 2026
Could Exelixis be the next big player in cancer treatment? Join us as we explore its potential and the risks involved in this exciting investment opportunity. 
Via The Motley Fool
News headline image
The Best Healthcare Stocks to Buy With $50 Right Now ↗
March 18, 2026
Even on a budget, you can get quality stocks. 
Via The Motley Fool
News headline image
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗
February 28, 2026
The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics. 
Via The Motley Fool
Topics Lawsuit
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
February 24, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026 ↗
February 20, 2026
The stock is coming off a strong year. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Exelixis Reports Solid Earnings—Are New Highs Back on the Table? ↗
February 12, 2026
Via MarketBeat
News headline image
Exelixis (EXEL) Q4 2025 Earnings Call Transcript ↗
February 10, 2026
Exelixis (EXEL) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
February 10, 2026
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap